Bibliography
- Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review [see comment]. [review] [38 refs]. Am J Health System Pharm 2005;62(7):691-9
- Morrison JC, Pollack IP. Glaucoma science and practice. Thieme: New York; 2003. p. 383
- Allen RC. Medical management of glaucoma. In: Principles and practice of ophthalmology. 2nd edition. WB Saunders Co.: Philadelphia; 2000. p. 2898
- Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113(12):1514-7
- Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48(Suppl 1):S47-51
- Bylund DB, Chacko DM. Characterization of alpha-2 adrenergic receptor subtypes in human ocular tissue homogenates. Invest Ophthalmol Vis Sci 1999;40(10):2299-306
- WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42(12):2849
- Kent AR, Nussdorf JD, David R, et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001;4(108):784-7
- Albert DM, Jakobiec FA. Principles and practice of ophthalmology. 2nd edition. WB Saunders Co.: Philadelphia; 2000. p. 2897-8
- Barnebey HS. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993;100:1083
- Zimmerman TJ. Textbook of ocular pharmacology. Lippincott-Raven: Philadelphia; 1997. p. 250
- Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104(1):131-6. Published erratum appears in: Ophthalmology 1997;104(3):346
- Katz LJ; and the Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily versus timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol 1999;127(1):21-6
- Fung AT, Reid SE, Jones MP, et al. Meta-analysis of randomized controlled trials comparing latanproast with brimonidine in the treatmet of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Opthalmol 2007;91:62-8
- Centofanti MM. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefe's archive for clinical and experimental ophthalmology 2000;238:302-5
- thoe Schwartzenberg GWS, Buys YM. Efficacy of brimonidine 0.2% as adjunvtive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999;106(8):1616-20
- Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocular Pharm Ther 2005;21(4):337-48
- Hoyung PFJ, van Beck LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59(3):411-34
- Hegde V, Robinson R, Dean F, et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007;114(2):362-6
- Chan K, Testa M, McClusky P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocular Pharm Ther 2007;23(4):372-5
- Al-Shahwan S, l-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005;112(12):2143-8
- Soto-Perez-de-Celis E, Skvirsky DO, Cisneros BG. Unintentional ingestion of brimonidine antiglaucoma drops: a case report and review of the literature. Pediatric Emerg Care 2007;23(9):657-8